BioCancell Ltd. (the “Company”) hereby announces the convening of an Extraordinary General Meeting (the “Meeting”) of the Company’s shareholders, to be held on Monday, July 23, 2018 at 10:00 a.m. IDT, at the Company’s offices, at 1/3 High-Tech Village, Givat Ram, Jerusalem, Israel. Telephone for inquiries: +972-2-548-6555. An adjourned Meeting, if required, will take place on Monday, July 30, 2018, at the same place and at the same time or at such other time, as the Board of Directors shall determine in a notice to the shareholders.
The agenda of the Meeting is approval of the change of the Company’s name to Anchiano Therapeutics Ltd. or any similar name approved by the Israeli Companies Registrar and approved by the Company’s Board of Directors and to amend the Company’s Articles of Association accordingly, and to authorize the Company’s management to take all actions required to change the Company’s name.
The date of record for determining the entitlement of shareholders to participate and vote at the Meeting: Monday, July 2, 2018.
The last date for the delivery of a voting card to the Company: up to four (4) hours prior to the time of convening the Meeting.
The last date for the delivery of position notices to the Company by shareholders: up to ten (10) days before the date of convening the Meeting.
A shareholder may vote on a subject on the agenda of the Meeting by means of a voting card. In addition, an unregistered shareholder may also vote through the electronic voting system operating under Article Two of Chapter 2 of the Securities Law, 1968. A vote by means of an electronic voting card shall be possible from the end of the date of record until six (6) hours prior to the time of convening the Meeting.
For further information regarding the meeting and the proposed resolutions on its agenda, see the report on the distribution website of the Israel Securities Authority at http://www.magna.isa.gov.il and on the website of the Tel Aviv Stock Exchange Ltd. at http://maya.tase.co.il.
Comments are closed.